Antigenic characteristics and stability of microencapsulated Mycoplasma hyopneumoniae vaccine
1Department of Chemical Engineering, National Tsing Hua University, Hsinchu, Taiwan, ROC.
Abstract:
The in vitro stability (temperature, pH, and trypsin) of Mycoplasma hyopneumoniae antigen (MHA) with and without enteric-coated microencapsulation were examined. Microencapsulation of MHA with cellulose acetate phthalate (CAP) is an effective route to produce enteric-coated vaccine microspheres for oral administration. The effect of temperature on the rate of inactivation of MHA was studied by exposing MHA to various temperatures, such as 25, 37, 50 and 60 degrees C. The MHA microspheres were thermally more stable than that of the unencapsulated MHA. The kinetic parameters were observed to follow an Arrhenius-type temperature dependence. The MHA microspheres were also more stable in acidic regions (pH 1.2-4.0) than that of the free one. The enteric-coated MHA microspheres exhibited an excellent enteric function to prevent acidic degradation. A model similar to the well-known Michaelis-Menten equation was formulated to describe the effect of trypsin on the antigenic degradation of MHA. The equilibrium constant K(A) and the maximum reaction velocity V(m) were obtained from experimental data for both free and microencapsulated MHA. Both K(A) and V(m) values of the microencapsulated MHA were smaller than that of the free one, i.e., the resistance to proteolytic enzyme such as trypsin was enhanced by microencapsulation. The storage stability of enteric-coated MHA microspheres has been satisfactorily prolonged that they could preserve more than 90% of original antigenicity after 30 days, and over 80% of antigenicity of MHA was retained in the microspheres for 95 days when it was stored at 4 degrees C.
Insights
Enteric-coated microencapsulation significantly enhances the stability of Mycoplasma hyopneumoniae antigen (MHA). This oral vaccine delivery method protects MHA from heat, acidic conditions, and enzymatic degradation, improving its shelf life.
Area of Science:
- Veterinary immunology
- Biopharmaceutical formulation
- Microbiology
Background:
- Mycoplasma hyopneumoniae antigen (MHA) is crucial for developing oral vaccines.
- Assessing MHA's in vitro stability is essential for vaccine efficacy.
- Microencapsulation offers a potential strategy to improve antigen stability.
Purpose of the Study:
- To evaluate the in vitro stability of MHA under various conditions (temperature, pH, trypsin).
- To determine the effectiveness of enteric-coated microencapsulation using cellulose acetate phthalate (CAP) for MHA.
- To assess the potential of microencapsulated MHA for oral vaccine applications.
Main Methods:
- MHA was subjected to different temperatures (25-60°C), pH levels (acidic range), and trypsin digestion.
- Microencapsulation of MHA was achieved using CAP to create enteric-coated microspheres.
- Kinetic parameters (Arrhenius-type dependence, Michaelis-Menten model) were analyzed.
Main Results:
- Enteric-coated MHA microspheres demonstrated superior thermal stability compared to unencapsulated MHA.
- Microspheres effectively protected MHA from degradation in acidic environments (pH 1.2-4.0).
- Microencapsulation significantly reduced trypsin degradation of MHA, indicated by lower K(A) and V(m) values.
Conclusions:
- Enteric-coated microencapsulation with CAP enhances MHA stability against temperature, pH, and enzymatic challenges.
- This formulation strategy prolongs the storage stability of MHA, retaining over 80% antigenicity for 95 days at 4°C.
- Microencapsulated MHA shows promise for developing stable and effective oral vaccines against Mycoplasma hyopneumoniae.
More Related Videos
07:32Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
Published on: September 1, 2023
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
Related Concept Videos
Vaccinations
Vaccine Production
Vaccines
Atypical Pneumonia
